Mayne Pharma Group Future Growth
Future criteria checks 4/6
Mayne Pharma Group is forecast to grow earnings and revenue by 111.4% and 9.3% per annum respectively while EPS is expected to grow by 111.4% per annum.
Key information
111.4%
Earnings growth rate
111.4%
EPS growth rate
Pharmaceuticals earnings growth | 32.3% |
Revenue growth rate | 9.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 02 Dec 2024 |
Recent future growth updates
Recent updates
A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb
Sep 01Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade
Mar 06Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers
Dec 03Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?
Dec 01Is Mayne Pharma Group (ASX:MYX) A Risky Investment?
Apr 12Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade
Mar 01We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope
Nov 16Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt
Nov 10Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt
May 17Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?
Mar 22How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?
Mar 01What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition
Feb 08Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit
Jan 18Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares
Dec 27Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?
Dec 09A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation
Nov 24Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2027 | 521 | 14 | N/A | N/A | 1 |
6/30/2026 | 457 | -4 | N/A | -9 | 2 |
6/30/2025 | 418 | -15 | N/A | -24 | 2 |
6/30/2024 | 388 | -169 | -36 | -15 | N/A |
12/31/2023 | 319 | -274 | -34 | -15 | N/A |
9/30/2023 | 251 | -296 | -148 | -29 | N/A |
6/30/2023 | 184 | -317 | -262 | -43 | N/A |
12/31/2022 | 59 | -257 | -287 | -64 | N/A |
9/30/2022 | 108 | -233 | -153 | -36 | N/A |
6/30/2022 | 157 | -209 | -19 | -7 | N/A |
3/31/2022 | 250 | -151 | -13 | 3 | N/A |
12/31/2021 | 342 | -93 | -7 | 13 | N/A |
9/30/2021 | 372 | -151 | 14 | 36 | N/A |
6/30/2021 | 401 | -208 | 34 | 59 | N/A |
3/31/2021 | 420 | -232 | 56 | 82 | N/A |
12/31/2020 | 439 | -256 | 78 | 106 | N/A |
9/30/2020 | 448 | -174 | 72 | 109 | N/A |
6/30/2020 | 457 | -93 | 65 | 113 | N/A |
3/31/2020 | 467 | -196 | 61 | 109 | N/A |
12/31/2019 | 478 | -300 | 56 | 106 | N/A |
9/30/2019 | 502 | -290 | 40 | 106 | N/A |
6/30/2019 | 525 | -279 | 25 | 107 | N/A |
3/31/2019 | 543 | -118 | 28 | 117 | N/A |
12/31/2018 | 561 | 43 | 31 | 127 | N/A |
9/30/2018 | 546 | -46 | 29 | 124 | N/A |
6/30/2018 | 530 | -134 | 27 | 121 | N/A |
3/31/2018 | 526 | -146 | N/A | 111 | N/A |
12/31/2017 | 521 | -158 | N/A | 100 | N/A |
9/30/2017 | 547 | -35 | N/A | 42 | N/A |
6/30/2017 | 573 | 89 | N/A | -15 | N/A |
3/31/2017 | 504 | 90 | N/A | -30 | N/A |
12/31/2016 | 435 | 91 | N/A | -44 | N/A |
9/30/2016 | 351 | 64 | N/A | 5 | N/A |
6/30/2016 | 267 | 37 | N/A | 54 | N/A |
3/31/2016 | 238 | 30 | N/A | 49 | N/A |
12/31/2015 | 209 | 23 | N/A | 44 | N/A |
9/30/2015 | 175 | 15 | N/A | 33 | N/A |
6/30/2015 | 141 | 8 | N/A | 22 | N/A |
3/31/2015 | 137 | 12 | N/A | 21 | N/A |
12/31/2014 | 133 | 17 | N/A | 20 | N/A |
9/30/2014 | 138 | 19 | N/A | 23 | N/A |
6/30/2014 | 143 | 21 | N/A | 26 | N/A |
3/31/2014 | 135 | 15 | N/A | 24 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MYX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: MYX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MYX is expected to become profitable in the next 3 years.
Revenue vs Market: MYX's revenue (9.3% per year) is forecast to grow faster than the Australian market (6% per year).
High Growth Revenue: MYX's revenue (9.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MYX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/06 01:01 |
End of Day Share Price | 2025/02/06 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mayne Pharma Group Limited is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
William Dunlop | BofA Global Research |
Martyn Jacobs | Canaccord Genuity |
Elyse Shapiro | Canaccord Genuity |